Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.15 USD | +3.66% | +7.03% | +50.85% |
25/04 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
24/04 | Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study | MT |
Sales 2024 * | 321M 26.77B | Sales 2025 * | 606M 50.56B | Capitalization | 3.96B 330B |
---|---|---|---|---|---|
Net income 2024 * | -149M -12.42B | Net income 2025 * | 30M 2.5B | EV / Sales 2024 * | 16.9 x |
Net Debt 2024 * | 1.46B 122B | Net Debt 2025 * | 1.28B 106B | EV / Sales 2025 * | 8.63 x |
P/E ratio 2024 * |
-23.7
x | P/E ratio 2025 * |
136
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | +3.66% | ||
Current month | +50.85% | ||
Current year | +50.85% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 02/18/02 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 01/20/01 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 16/22/16 |
Helga Zharov
LAW | General Counsel | 57 | 01/20/01 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 02/18/02 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 14.15 | +3.66% | 248,476 |
25/24/25 | 13.65 | +0.81% | 65,564 |
24/24/24 | 13.54 | +1.04% | 191,089 |
23/24/23 | 13.4 | +0.53% | 195,834 |
22/24/22 | 13.33 | +0.83% | 184,812 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALVO Stock
- ALVO Stock